# Anti-RSV Study in Chinese Patients (ASCENT)

> **NCT03699202** · PHASE2 · UNKNOWN · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 160 (estimated)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** AK0529
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03699202
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-29
- **Primary completion:** 2020-01-31
- **Final completion:** 2020-06-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2019-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03699202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03699202, "Anti-RSV Study in Chinese Patients (ASCENT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03699202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*